Side Chat: Modern Analgesic Trials

Subscribe or renew to PPM

11 Articles in this Series

Introduction

A PAINWeek 2019 preview with EVP Debra Weiner

Comparing Marijuana and Hemp

Fibromyalgia: What’s New in Diagnosis and Pain Management

Life Hacks to Teach Patients with Chronic Pain

Managing Pain (and Function) in Osteoarthritis: Are Patients and Physicians on the Same Page?

Marijuana: How to Proceed When Controlled Substances are Involved

Menopause Comes with More than Mood Swings - It Deserves its Place Among Chronic Pain Conditions

More APPs Are Coming to the Forefront of Pain Care

Motivational Interviewing and Its Extension into Pain Management

Revisiting Documentation

Side Chat: Modern Analgesic Trials

By Srinivas R. Nalamachu, MD and Angie Drakulich, MA, PPM Executive Editor

A Q&A after PAINWeek 2019, with PPM Board Member Srinivas Nalamachu, MD, of the Mid America PolyClinic, Kansas. Dr. Srinivas led a panel on modern analgesic trials at PAINWeek 2019.

PPM: In general, how do analgesic trials differ from other more general drug trials?

Dr. Nalamachu: Primary endpoints in the clinical trials are mostly subjective with no objective evidence to measure. Multiple failed trials in the recent past have raised concerns about placebo response. Sponsors are spending more time and resources on educating the research subjects to minimize the placebo response. They are also educating research personnel to better prepare them for proper evaluation of the subjects and their responses.

PPM: As clinicians consider safety and efficacy trials in today’s healthcare context, what types of red flags should they look for?

Dr. Nalamachu: Any time you see data that is ‘too good to be true’ in terms of efficacy or safety, we as clinicians should a take a closer look at the study design and the study population.

PPM: What is one way that analgesic trials may improve?

Dr. Nalamachu: Based on the demographics of patient populations and the knowledge from animal studies that we have to date, it would be wise to encourage enrolling more female subjects in fibromyalgia and migraine studies going forward.

Remedy Health Media, LLC does not, by publication of the advertisements contained herein, express endorsement or verify the accuracy and effectiveness of the products and claims contained therein. Remedy Health Media, LLC disclaims any liability for damages resulting from the use of any product advertised herein and suggests that readers fully investigate the products and claims prior to purchasing. The views of the authors are not necessarily those of Remedy Health Media, LLC.

Practical Pain Management is sent without charge 10 times per year to pain management clinicians in the US.

Use of this website is conditional upon your acceptance of our user agreement.

close X

Side Chat: Modern Analgesic Trials

Subscribe to "Pain Monitor", a PPM eNewsletter for HCPs